
    
      A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III
      Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an
      Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response
      to Antidepressant Therapy
    
  